MoLEP—Co-creating a Mycobacterium leprae transmission interruption program for the Morogoro region, Tanzania

• Tanja Barth-Jaeggi ,

  * E-mail: tanja.barth-jaeggi@swisstph.ch

  Affiliations Swiss Tropical and Public Health Institute, Allschwil, Switzerland, University of Basel, Basel, Switzerland

  https://orcid.org/0000-0002-4453-5950

  ⨯
• Guy de Coulon,

  Affiliation Novartis Kenya Ltd., Nairobi, Kenya

  ⨯
• Issa Garimo,

  Affiliation German Leprosy and Tuberculosis Relief Association Tanzania, Dar es Salaam, Tanzania

  ⨯
• John Msaki,

  Affiliation National Tuberculosis and Leprosy Programme, Dodoma, Tanzania

  ⨯
• Liberate Mleoh,

  Affiliation National Tuberculosis and Leprosy Programme, Dodoma, Tanzania

  ⨯
• Riziki Kisonga,

  Affiliation National Tuberculosis and Leprosy Programme, Dodoma, Tanzania

  ⨯
• Sunil Modali,

  Affiliation Novartis Pharmaceuticals, London, United Kingdom

  ⨯
• Shaishav Panchal,

  Affiliation Novartis Healthcare Pvt. Ltd., Hyderabad, India

  ⨯
• Shigela Marco Njebele,

  Affiliation President’s Office – Regional Administration and Local Government, Dodoma, Tanzania

  ⨯
• Shamez Sunderji,

  Affiliation German Leprosy and Tuberculosis Relief Association Tanzania, Dar es Salaam, Tanzania

  ⨯
• Kihulya Mageda,

  Affiliation President’s Office – Regional Administration and Local Government, Dodoma, Tanzania

  ⨯
• Peter Steinmann

  Affiliations Swiss Tropical and Public Health Institute, Allschwil, Switzerland, University of Basel, Basel, Switzerland

  ⨯